Why Most Pharma Giants Are Underestimating the ATMP Commercialization Crisis
The gap between clinical promise and commercial viability in advanced therapy medicinal products is widening faster than most pharmaceutical executives realize, and it’s creating a bifurcated market where early movers capture disproportionate value while late entrants face structural disadvantages that capital alone cannot overcome.
The advanced therapy medicinal products sector stands at an inflection point where scientific breakthroughs are outpacing business model innovation. While gene therapies, cell therapies, and tissue-engineered products demonstrate unprecedented clinical outcomes, the industry faces a paradox: treatments that can cure diseases in single doses are colliding with reimbursement systems designed for chronic care models. Companies that fail to address this fundamental mismatch are discovering that regulatory approval is merely the beginning of a far more complex commercialization challenge.
Request Report Sample: https://marketmindsadvisory.co....m/request-sample/?re
Why This Market Shift Matters Now
The traditional pharmaceutical playbook is failing in the ATMP space, and the consequences are materializing faster than anticipated. Several appro